Fuente: FierceBiotech AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted partners will start by testing ivonescimab with AstraZeneca’s CLDN18.2-directed ADC in gastrointestinal cancers.